Rathbones Group PLC lessened its position in Merck & Co., Inc. (NYSE:MRK – Free Report) by 6.0% during the third quarter, Holdings Channel reports. The institutional investor owned 195,142 shares of the company’s stock after selling 12,400 shares during the quarter. Rathbones Group PLC’s holdings in Merck & Co., Inc. were worth $28,356,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Curry Webb Wealth Management LLC acquired a new position in Merck & Co., Inc. in the third quarter worth approximately $29,000. Horizons Wealth Management bought a new position in shares of Merck & Co., Inc. in the third quarter valued at $30,000. Bullseye Investment Management LLC bought a new position in shares of Merck & Co., Inc. in the second quarter valued at $27,000. Clal Insurance Enterprises Holdings Ltd lifted its position in shares of Merck & Co., Inc. by 69.5% during the 3rd quarter. Clal Insurance Enterprises Holdings Ltd now owns 222 shares of the company’s stock valued at $32,000 after acquiring an additional 91 shares during the last quarter. Finally, Graney & King LLC lifted its position in shares of Merck & Co., Inc. by 400.0% during the 2nd quarter. Graney & King LLC now owns 250 shares of the company’s stock valued at $32,000 after acquiring an additional 200 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.
Key Stories Impacting Merck & Co., Inc.
These are some of the MRK stories that stood out recently:
- Positive Sentiment: A German court overturned an injunction that had restricted Merck from distributing and offering Keytruda SC in Germany. The ruling removes an immediate obstacle to the formulation, although Halozyme says it will pursue a new patent lawsuit. Zacks: HALO Faces Legal Setback in Germany Over MRK's Keytruda SC
- Positive Sentiment: Merck partnered with Isomorphic Labs to discover small-molecule oncology drug candidates, combining the AI drug-design company’s approach with Merck’s data and drug-development expertise. The collaboration could support longer-term growth as Merck prepares for Keytruda’s eventual patent expiry. Business Wire: Merck and Isomorphic Labs Enter Strategic Research Collaboration
- Negative Sentiment: Merck has stopped development of nemtabrutinib and ended its Phase 3 BELLWAVE studies after concluding the drug’s benefit-risk profile did not justify continuing. This removes a late-stage blood-cancer candidate from its pipeline. Yahoo Finance: What Does Merck Losing Nemtabrutinib Mean For Its Blood Cancer Pipeline?
Insider Transactions at Merck & Co., Inc.
In other news, EVP Richard Deluca sold 58,185 shares of the business’s stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $148.01, for a total transaction of $8,611,961.85. Following the transaction, the executive vice president owned 112,955 shares in the company, valued at approximately $16,718,469.55. The trade was a 34.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.17% of the stock is owned by corporate insiders.
Wall Street Analyst Weigh In
MRK has been the subject of several research reports. Berenberg Bank raised their price objective on Merck & Co., Inc. from $127.00 to $137.00 and gave the stock a “hold” rating in a research note on Friday, September 11th. Citigroup raised their target price on shares of Merck & Co., Inc. from $125.00 to $145.00 and gave the stock a “neutral” rating in a report on Monday, October 12th. Zacks Research upgraded shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a report on Tuesday. Morgan Stanley cut their price target on shares of Merck & Co., Inc. from $179.00 to $177.00 and set an “overweight” rating on the stock in a report on Wednesday, October 7th. Finally, Freedom Broker upped their price target on shares of Merck & Co., Inc. from $125.00 to $140.00 and gave the company a “hold” rating in a research report on Monday, November 2nd. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $155.74.
View Our Latest Analysis on Merck & Co., Inc.
Merck & Co., Inc. Trading Up 0.6%
Shares of NYSE:MRK opened at $133.56 on Friday. The company has a current ratio of 1.35, a quick ratio of 1.14 and a debt-to-equity ratio of 1.11. The stock has a market capitalization of $329.26 billion, a PE ratio of 137.69, a P/E/G ratio of 6.62 and a beta of 0.13. The firm has a fifty day moving average price of $145.28 and a 200 day moving average price of $129.29. Merck & Co., Inc. has a 1 year low of $95.36 and a 1 year high of $156.92.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The company reported $2.49 earnings per share for the quarter, beating analysts’ consensus estimates of $2.09 by $0.40. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 3.64%. The business had revenue of $18.09 billion for the quarter, compared to the consensus estimate of $17.33 billion. During the same period last year, the business earned $2.58 EPS. The firm’s revenue was up 4.7% compared to the same quarter last year. Analysts expect that Merck & Co., Inc. will post 2.82 EPS for the current fiscal year.
Merck & Co., Inc. Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 8th. Stockholders of record on Tuesday, December 15th will be given a $0.88 dividend. This is a positive change from Merck & Co., Inc.’s previous quarterly dividend of $0.85. This represents a $3.52 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend is Tuesday, December 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 350.52%.
Merck & Co., Inc. Company Profile
Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.
Further Reading
- Five stocks we like better than Merck & Co., Inc.
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
